首页> 美国卫生研究院文献>Oncology Letters >BRAFV600E mutation contributes papillary thyroid carcinoma and Hashimoto thyroiditis with resistance to thyroid hormone: A case report and literature review
【2h】

BRAFV600E mutation contributes papillary thyroid carcinoma and Hashimoto thyroiditis with resistance to thyroid hormone: A case report and literature review

机译:BRAFV600E突变导致甲状腺乳头状癌和桥本甲状腺炎对甲状腺激素具有抵抗性:病例报告和文献复习

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Resistance to thyroid hormone (RTH) is a rare autosomal hereditary disorder characterized by increased serum thyroid hormone (TH) levels with unsuppressed or increased thyrotropin concentration. It remains unknown whether the coexistence of RTH with papillary thyroid carcinoma (PTC) and Hashimoto thyroiditis (HT) is incidental or whether it possesses a genetic or pathophysiological association. In the present study, a case of RTH with PTC and HT in an 11-year-old Chinese patient was examined and the clinical presentation of RTH with PTC was discussed. In addition, the possible associations between RTH, PTC and HT were determined. HT was confirmed in the patient using an autoimmune assay and thyroid ultrasound. RTH was diagnosed on the basis of clinical manifestations, laboratory information and gene analysis, and PTC was diagnosed according to histological results. Results of BRAFV600E mutation analysis were positive. A literature review of 14 cases of RTH with PTC was included for comparison. The present case report indicates an association of RTH with PTC and HT coexistence in the patient. Close follow-up, histological evaluation and BRAFV600E mutation detection should be performed in each RTH case with HT, since a persistent increase in TSH may be a risk factor for the development of thyroid neoplasm.
机译:对甲状腺激素(RTH)的耐药性是一种罕见的常染色体遗传性疾病,其特征是血清甲状腺激素(TH)水平升高而促甲状腺激素浓度未抑制或升高。 RTH与乳头状甲状腺癌(PTC)和桥本甲状腺炎(HT)并存是偶然的,还是它具有遗传或病理生理学关联,目前尚不清楚。在本研究中,对一名11岁的中国患者进行PTC和HT的RTH病例进行了检查,并讨论了PTC进行RTH的临床表现。另外,确定了RTH,PTC和HT之间的可能关联。使用自身免疫测定和甲状腺超声在患者中确认了HT。根据临床表现,实验室信息和基因分析对RTH进行诊断,根据组织学结果对PTC进行诊断。 BRAF V600E 突变分析结果为阳性。文献回顾了14例PTC伴RTH的病例,以作比较。本病例报告表明患者中RTH与PTC和HT共存相关。对于每例伴有HT的RTH病例,应进行密切随访,组织学评估和BRAF V600E 突变检测,因为TSH持续升高可能是甲状腺肿瘤发展的危险因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号